Pharmacogenomic Implications for the Use of Antidepressant Medications

David A. Mrazek, M.D., F.R.C., Psych.

  At the completion of this session, the participant should be able to:

1)

Describe currently available pharmacogenomic technology

2)

Understand the implications of 2D6 gene testing for antidepressant selection

3)

Understand the implications of variability of the serotonin transporter gene